Corcept Therapeutics Incorporated (LON:0I3Q)
72.03
+1.01 (1.42%)
Apr 28, 2025, 4:42 PM BST
Corcept Therapeutics Employees
Corcept Therapeutics had 500 employees as of December 31, 2024. The number of employees increased by 148 or 42.05% compared to the previous year.
Employees
500
Change (1Y)
148
Growth (1Y)
42.05%
Revenue / Employee
1.08M GBP
Profits / Employee
223.23K GBP
Market Cap
5.68B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,315 |
Corcept Therapeutics News
- 3 days ago - Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today - Benzinga
- 5 days ago - CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 - Business Wire
- 6 days ago - Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss - Seeking Alpha
- 7 days ago - Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - Business Wire
- 13 days ago - It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - Seeking Alpha
- 21 days ago - Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - Business Wire
- 27 days ago - Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release - Seeking Alpha
- 27 days ago - Corcept Therapeutics Unusual Options Activity For April 01 - Benzinga